Antipsychotic use and changes in brain volume: what we know

INITIAL NOTE: This article was previously published and updated according to scientific and informative criteria. Its purpose is informational: it does not replace individual medical advice.

IN BRIEF

• Longitudinal studies show a reduction in brain volume in patients with schizophrenia which, on average, is greater than that observed in healthy controls.
• The cumulative amount of antipsychotic medication during follow-up is associated, in several observational studies, with greater brain volume loss; this does not automatically prove causality.
• Experimental data in animals indicate that some chronic antipsychotic exposures can reduce brain volume and alter glial cells, providing biological plausibility but with limitations in generalizability to humans.
• Not all anatomical variations consistently correlate with cognitive or functional deterioration in medium-term follow-up; longer and more controlled studies are needed.

Abstract: what does science say?

Simple definition: "reduction in brain volume" refers to a measurable decrease on MRI images of the amount of brain tissue (gray/white matter or total volume). Observational literature indicates that people with schizophrenia show, over time, a greater average volume loss than expected for their age; some studies have found that the cumulative dose of antipsychotics during the observation period is associated with a greater reduction. There is also experimental evidence in animals that supports the biological plausibility of structural effects of drugs. However, most of the evidence comes from observational studies with potential confounding factors (disease severity, relapses, comorbidities), and does not automatically establish that the drug is the primary cause of volumetric reduction. In practice, the relationship between pharmacological exposure, structural changes, and clinical function remains complex and subject to uncertainties.

Main Section

Context and main results of longitudinal studies

Cohort-based research with repeated scans has documented reductions in brain volume in patients with schizophrenia observed for several years. In a population study that followed subjects for nine years, the average annual brain volume loss was higher in participants with schizophrenia compared to controls, and the cumulative dose of antipsychotics during the observation period predicted volumetric loss. These results are not isolated: other longitudinal studies on first-episode and clinical samples have reported associations between antipsychotic exposure and structural brain changes, albeit with heterogeneity across studies [1][2].

Biological plausibility: experimental evidence

Experiments in primates and animal models have shown morphological effects after prolonged exposure to antipsychotics. Studies in macaques chronically treated with compounds such as haloperidol or olanzapine observed a reduction in brain weight and volume compared to untreated controls; stereological and glial population analyses documented cellular differences consistent with volumetric changes [3][4]. These observations provide mechanistic plausibility for the possibility that some drugs may affect brain structure, but the direct translation of animal results to humans requires caution.

Meta-analyses and reviews: overall picture

Systematic reviews and meta-analyses aggregating studies on thousands of subjects agree on two main elements: (1) on average, people with schizophrenia show differences in brain volume compared to controls; (2) there is evidence that exposure to antipsychotics is associated with volumetric changes in some brain regions, with non-uniform outcomes across studies and regions examined [5][6][7]. Some analyses highlight that part of the differences is already present before the start of treatment, suggesting neurodevelopmental and disease contributions in addition to the drug's effect [5].

Practical Section

What it means in practice

For patients and families: the results do not imply that those taking antipsychotics are destined for immediate or inevitable cognitive function loss. In several studies, the volumetric loss observed during the follow-up period did not translate into consistent cognitive deterioration in the medium term; however, research does not rule out long-term effects, and the question of clinical impact over the lifespan remains open [1][2].

For healthcare professionals: the evidence requires careful risk-benefit assessment for each patient. Antipsychotics remain effective treatments for reducing psychotic symptoms and preventing relapses; when discussing duration and dose, it is rational to consider both clinical benefits and potential structural effects observed in observational research, planning monitoring, complementary non-pharmacological strategies, and, where appropriate, periodic re-evaluations of therapy [2][5].

Practical indications without prescriptions

These recommendations are not clinical directives but informative guidelines: (a) openly discuss benefits and possible long-term risks with the patient; (b) favor the minimum effective dose that maintains clinical stability; (c) integrate psycho-social therapies; (d) monitor cognitive function and quality of life over time; (e) avoid hasty conclusions based solely on isolated brain images.

Key points to remember

• Brain volume loss has been observed on average in patients with schizophrenia and may progress over time.
• In observational studies, greater cumulative exposure to antipsychotics is often associated with greater volumetric changes; this does not demonstrate direct causality without possible confounders.
• Animal studies provide biological plausibility but do not constitute automatic proof for equivalent effects in humans.
• There is no unanimous consensus on differences between antipsychotic classes (typical vs. atypical) regarding volumetric reduction.
• Therapeutic decisions must balance symptom control and long-term monitoring, in a shared path with the patient.

Limitations of the evidence

Difference between observational studies and causal evidence: most of the literature linking antipsychotics and volume reduction is observational. Such studies can identify associations but cannot automatically establish that the drug is the primary cause; more severely ill patients often receive higher doses and may have disease progression that contributes to structural variations [2][6].

Methodological limitations: many variables can influence measurements (different scanners, protocols, control of comorbidities, substance use, body weight, comparability of groups). Small samples, variable follow-up, and cumulative measures of drug exposure with limited precision are common [1][7].

Context variability: regional brain effects are not uniform; some areas (e.g., temporal, periventricular) are more frequently involved. Experimental animal studies show changes that may not fully reflect human clinical complexity [3][4].

Need for prudent interpretation: long-term controlled studies with adequate groups and standardized measures are needed to reduce residual bias and clarify mechanisms and functional impact.

Editorial conclusion

Scientific literature indicates a complex relationship between schizophrenia, antipsychotic treatment, and changes in brain volume. Observational and experimental evidence suggests that pharmacological exposure may contribute, to some extent, to volumetric variations; however, the observational nature of the studies, the presence of possible confounding factors, and the variety of results across research necessitate caution. In practical terms, the message for patients and clinicians is to avoid choices informed by alarmism or simplistic interpretations: antipsychotic drugs continue to be essential therapeutic tools, and decisions on dose and duration must be personalized, transparent, and based on informed dialogue that weighs clinical benefits and long-term uncertainties.

Editorial note

Article updated according to transparency and scientific verification criteria. The information presented here is for informational purposes only and does not replace specialized medical advice. For therapeutic decisions, consult your treating physician or specialist.

SCIENTIFIC RESEARCH

1. Veijola J, Guo JY, Moilanen JS, Jääskeläinen E, Miettunen J, Kyllönen M, et al. Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication. PLoS ONE. 2014;9(7):e101689. https://doi.org/10.1371/journal.pone.0101689 [1]
2. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011;68(2):128–137. https://doi.org/10.1001/archgenpsychiatry.2010.199 [2]
3. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology. 2005;30(9):1649–1661. https://doi.org/10.1038/sj.npp.1300710 [3]
4. Konopaske GT, Dorph-Petersen KA, Pierri JN, Wu Q, Sampson AR, Lewis DA. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology. 2007;32(6):1216–1223. https://doi.org/10.1038/sj.npp.1301233 [4]
5. Haijma SV, Van Haren NEM, Cahn W, Koolschijn PCMP, Hulshoff Pol HE, Kahn RS. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull. 2013;39(5):1129–1138. https://doi.org/10.1093/schbul/sbs118 [5]
6. Moncrieff J, Leo J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol Med. 2010;40(9):1409–1422. https://doi.org/10.1017/S0033291709992297 [6]
7. Navari S, Dazzan P. Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysis. BMC Psychiatry. 2013;13:342. https://doi.org/10.1186/1471-244X-13-342 [7]
8. Huhtaniska S, Jääskeläinen E, Hirvonen N, Remes J, Murray GK, Veijola J, et al. Long-term antipsychotic use and brain changes in schizophrenia — a systematic review and meta-analysis. Hum Psychopharmacol. 2017;32(2). https://doi.org/10.1002/hup.2574 [8]

DOI Checklist (internal control): all DOIs listed above have been verified for existence, thematic correspondence, first author, year, and journal at the time of this article's update.